Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 30, 2017British Journal of HaematologyOpen Access

Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions

View Full Paper
Ask AI
Bookmark
Share

Authors

Philippe MoreauPhilippe MoreauHôtel-Dieu de ParisEWEdwin de WitHôpital de Morges

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Moreau et al. (2017) studied this question.

synapsesocial.com/papers/6a0daa94cb02dac523a4e030https://doi.org/10.1111/bjh.14780
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma2003 · 2,659 citations
  2. 2Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma2016 · 23 citations
  3. 3Multiple Myeloma in the Older Adult: Better Prospects, More Challenges2014 · 93 citations
  4. 4Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma2016 · 122 citations
  5. 5Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma2016 · 160 citations